Furosemide for Accelerated Recovery of Blood Pressure Postpartum

• Status: Completed
• Trial end date: 2020-02-05
• Target enrollment: 0
• Participant gender: Female

Summary

A randomized, double-blind, placebo-controlled single center investigation of furosemide's effect on postpartum blood pressure control in pregnancies affected by hypertensive disorders of pregnancy

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Pennsylvania
• Treatments: Furosemide

Criteria

Inclusion Criteria:

• Hypertensive disorder of pregnancy diagnosed antepartum or intrapartum

• Gestational hypertension

• Pre-eclampsia with or without severe features

• Superimposed pre-eclampsia with or without severe features

• New diagnosis of HDP within 24 hours from delivery

• Postpartum, delivery ≥ 20 weeks estimated gestational age

• Age ≥18 years old

Exclusion Criteria:

• History of allergic reaction to furosemide

• High risk comorbidities for which treatment may be indicated or contraindicated: class C or higher diabetes mellitus, chronic kidney disease or baseline creatinine >1.2, cardiac disorders including cardiomyopathy, congenital heart disease, angina or coronary heart disease, rheumatic disease (lupus), sickle cell disease

• Baseline labs with K <3

• Use of furosemide or other diuretics antepartum or intrapartum

• Use of ototoxic agents including aminoglycosides (ie, Gentamicin for >1 dose), cephalosporins (ie Ancef >1 dose),

• Patient unstable for protocol per investigator's judgement